Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults

Clinical Drug Investigation

Volumn 33, Issue 6, 2013, Pages 441-449

  Perrino, Peter J ^a   Colucci, Salvatore V ^a   Apseloff, Glen ^b   Harris, Stephen C ^a  

^a PURDUE PHARMA L P   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; OXYGEN;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD OXYGEN TENSION; BURNING SENSATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENDOSCOPY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; NOSE DISCOMFORT; NOSE DISEASE; NOSE STUFFINESS; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINORRHEA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

ADMINISTRATION, INTRANASAL; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXYCODONE; SINGLE-BLIND METHOD; TABLETS; YOUNG ADULT;

EID: 84878717974     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0085-x     Document Type: Article

References (31)

1. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs. 2010;24(10):805-10.
2. Hamed E, Moe D. Development of tamper deterrent formulations: state of the pharmaceutical industry. Curr Drug Abuse Rev. 2010;3(3):139-46.
3. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648-60.
4. Osgood ED, Eaton TA, Trudeau JJ, et al. A brief survey to characterize oxycodone abuse patterns in adolescents enrolled in two substance abuse recovery high schools. Am J Drug Alcohol Abuse. 2012;38(2):166-70.
5. Inciardi JA, Surratt HL, Kurtz SP, et al. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8(2):171-83.
6. Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205-17.
7. Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J. 2010;7:24.
8. Lofwall MR, Moody DE, Fang WB, et al. Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol. 2012;52(4):600-6.
9. Cone EJ, Giordano J, Weingarten B. Laboratory based in vitro tamper testing of reformulated OxyContin: an iterative and incremental scientific approach. Poster presented at the College on Problem of Drug Dependence's 74th Annual Meeting. June 10-14, 2012; Palm Springs, CA.
10. Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004;18(4):17-30.
11. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18(3):255-63.
12. Webster LR. Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. Pain Manage. 2011;1(5):417-25.
13. Greene D. Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat J. 2005;84(8):512,514,516.
14. Yewell J, Haydon R, Archer S, et al. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol. 2002;111(2):174-7.
15. Jewers WM, Rawal YB, Allen CM, et al. Palatal perforation associated with intranasal prescription narcotic abuse. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(5):594-7.
16. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70(13):1657-75.
17. Lipman AG. What have we learned from OxyContin? J Pain Palliat Care Pharmacother. 2003;17(1):1-4.
18. Webster LR, Bath B, Medve RA, et al. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Pain Med. 2012;13(6):790-801.
19. Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57(11):1640-65.
20. Matsuyama T, Morita T, Horikiri Y, et al. Influence of fillers in powder formulations containing N-acetyl-l-cysteine on nasal peptide absorption. J Control Release. 2007;120(1-2):88-94.
21. Marsch LA, Bickel WK, Badger GJ, et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299(3):1056-65.
22. Comer SD, Ashworth JB, Sullivan MA, et al. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5(4):203-12.
23. US Department of Health and Human Services. Guidance for Industry: Assessment of Abuse Potential of Drugs. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. Accessed 11 Sept 2012.
24. Perrino PJ, Colucci S, Harris S, et al. Evaluation of abuse potential of crushed and intranasally administered oxycodone tablets. Abstract presented at the College on Problem of Drug Dependence's 74th Annual Meeting. June 10-14, 2012; Palm Springs, CA.
25. Sellers E, Perrino PJ, Harris S, et al. Relative attractiveness of reformulated OxyContin®: comparative assessment of tampering potential and recreational drug user preferences for opioid formulations. Abstract presented at the College on Problem of Drug Dependence's 74th Annual Meeting. June 10-14, 2012; Palm Springs, CA.
26. Coplan PM, Chilcoat HD, Baumgartner T, et al. Design of a post-marketing study program to assess the effects of a reformulated extended-release oxycodone tablet on its abuse [abstract]. Pharmacoepidemiol Drug Saf. 2012;21(suppl 3):446 (Abstract 963).
27. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated OxyContin: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2012. (Published online ahead of print).
28. DeVeaugh-Geiss A, Leukefeld C, Havens J, et al. Abuse of extended-release (ER) and immediate-release oxycodone in Kentucky following introduction of reformulated ER oxycodone. Abstract presented at: PAIN Week 2012. September 5-8, 2012; Las Vegas, NV.
29. Davis J, Severtson SG, Bucher-Bartelson B, et al. Reduction in extended release (ER) oxycodone diversion rates following the introduction of a reformulated ER oxycodone product. Abstract presented at: International Association for the Study of Pain's 14th World Congress on Pain; August 27-21, 2012; Milan, Italy.
30. Bucher-Bartelson B, Severtson S, Davis J, et al. A comparison of the street price of original and reformulated ER oxycodone. Abstract presented at: International Association for the Study of Pain's 14th World Congress on Pain; August 27-21, 2012; Milan, Italy.
31. US Department of Health and Human Services. Guidance for Industry: abuse-deterrent opioids - evaluation and labeling. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed 19 March 2013.